A Randomized Phase II Trial Of Radiation Therapy And Cisplatin Alone Or In Combination With Intravenous Triapine In Women With Actively Diagnosed Bulky Stage IB2, Stage II, IIIB, Or IVA Cancer Of The Uterine Cervix Or Stage II-IVA Vaginal Cancer Read more
Phase III Randomized Study Of Concurrent Chemotherapy And Pelvic Radiation Therapy With Or Without Adjuvant Chemotherapy In High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy Read more
A Phase 3, Randomized, Double-Blind Study Of Pembrolizumab Versus Placebo In Combination With Paclitaxel With Or Without Bevacizumab For The Treatment Of Platinum-Resistant Recurrent Ovarian Cancer (KEYNOTE-B96 / ENGOT-Ov65) Read more
A Randomized Phase III, Two-Arm Trial Of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy In Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma Of The Ovary Or Peritoneum Read more
NRG Oncology, Protocol: NRG-GY020, PI: Dr. Mcnamara, Title: A Phase III Randomized Trial Of Radiation +/- Mk-3475 (Pembrolizumab) For Actively Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (Dmmr) Endometrioid Endometrial Cancer Read more
An Open-Label, Randomized Phase 3 Study Of MK-6482 Versus Everolimus In Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 And VEGF-Targeted Therapies Read more
A Phase 2, Randomized, Open-Label Three-Arm Clinical Study To Evaluate The Safety And Efficacy Of Lenvatinib (E7080/MK-7902) In Combination With Pembrolizumab (MK-3475) Versus Standard Of Care Chemotherapy And Lenvatinib Monotherapy In Participants With Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy And Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009) Read more
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Of Infigratinib For The Adjuvant Treatment Of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302) Read more
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Clinical Study Of Pembrolizumab (MK-3475) With Or Without Lenvatinib (E7080/MK-7902) To Evaluate The Safety And Efficacy Of Pembrolizumab And Lenvatinib As 1L Intervention In A PD-L1 Selected Population Of Participants With Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) Read more
